

1 **Assessing the impact of preventive mass vaccination campaigns on**
2 **yellow fever outbreaks in Africa : a population-level self-controlled**
3 **case-series study**

4
5 *Kévin Jean^{1,2,3}, Hanaya Raad^{1,2,4}, Katy A. M. Gaythorpe³, Arran Hamlet³, Judith E.*
6 *Mueller^{2,4}, Dan Hogan⁵, Tewodaj Mengistu⁵, Heather J. Whitaker^{6,7}, Tini Garske³,*
7 *Mounia N. Hocine^{1,2}*

8
9
10 ¹ *Laboratoire MESuRS, Conservatoire national des Arts et Métiers, Paris, France*

11 ² *Unité PACRI, Institut Pasteur, Conservatoire National des Arts et Métiers, Paris,*
12 *France*

13 ³ *MRC Centre for Global Infectious Disease Analysis, Department of Infectious*
14 *Disease Epidemiology, Imperial College London, United Kingdom*

15 ⁴ *EHESP French School of Public Health, Paris, France*

16 ⁵ *Gavi, the Vaccine Alliance, Geneva, Switzerland*

17 ⁶ *Statistics, Modelling and Economics Department, National Infection Service, Public*
18 *Health England, Colindale, London, United Kingdom*

19 ⁷ *Department of Mathematics & Statistics, The Open University, Milton Keynes,*
20 *United Kingdom*

21
22 **Corresponding author:** kevin.jean@lecnam.net

23

24

25

26 **ABSTRACT**

27

28 **Introduction:**

29 The Eliminate Yellow fever Epidemics (EYE) strategy was launched in 2017 in response to the
30 resurgence of yellow fever in Africa and the Americas. The strategy relies on several vaccination
31 activities, including preventive mass vaccination campaigns (PMVCs). However, by how much PMVCs
32 are associated with a decreased risk of outbreak to occur has not yet been quantified.

33

34 **Methods and Findings:** We used the self-controlled case series (SCCS) method to assess the
35 association between the occurrence of yellow fever outbreaks and the implementation of PMVCs at
36 the province level in the African endemic region. As all time-invariant confounders are implicitly
37 controlled for, the SCCS method is an alternative to classical cohort or case-control study designs
38 when the risk of residual confounding is high, in particular confounding by indication.

39 The location and dates of outbreaks were identified from international epidemiological records, and
40 information on PMVCs was provided by coordinators of vaccination activities and international
41 funders. The study sample consisted of provinces that were both affected by an outbreak and
42 targeted for a PMVC between 2005 and 2018. We compared the relative incidence of outbreaks
43 before and after the implementation of a PMVC. The sensitivity of our estimates to a range of
44 assumptions was explored, and the results of the SCCS method were compared to those obtained
45 through a retrospective cohort study design. We further derived the number of yellow fever
46 outbreaks that have been prevented by PMVCs.

47 The study sample consisted of 33 provinces from 11 African countries. Among these, outbreaks
48 occurred during the pre-PMVC period in 26 (79%) provinces versus 7 (21%) occurring in the post-
49 PMVC period. At the province level, the post-PMVC period was associated with a 86% reduction (95%
50 Confidence interval 66% to 94%, p-value<0.001) in the risk of outbreak as compared to the pre-PMVC
51 period. This negative association was robustly observed across a range of sensitivity analyses,
52 especially when using quantitative estimates of vaccination coverage as alternative exposure, or
53 when varying the observation period. Conversely, the results of the cohort-style analyses were highly
54 sensitive to the choice of covariates included in the model. Based on the SCCS results, we estimated
55 that PMVCs were associated with a 34% (22% to 45%) reduction in the number of outbreaks in Africa
56 over the study period.

57 A limitation of our study is the fact that it does not account for potential time-varying confounders,
58 such as changing environmental drivers of yellow fever or possibly improved disease surveillance.

59

60 **Conclusion:** In this study, we provide new empirical evidence of the high preventive impact of PMVCs
61 on yellow fever outbreaks. This study illustrates that the SCCS method can be advantageously applied
62 at the population level in order to evaluate a public health intervention.

63

64 **AUTHOR SUMMARY**

65

66 **Why Was This Study Done?**

- 67
- 68 • Yellow fever is a mosquito-borne vaccine-preventable disease that may cause large urban outbreaks, especially in tropical African regions.
 - 69 • Since 2006, Preventive Mass Vaccination Campaigns (PMVCs) have been implemented in many African provinces. These are large scale vaccination campaigns targeting all or most age group in a specific area.
 - 70
 - 71
 - 72 • The preventive impact PMVCs may have on the risk of yellow fever outbreak has not been
 - 73 quantified yet.

74 **What Did the Researchers Do and Find?**

- 75
- 76 • We used the self-controlled case series (SCCS) method to assess the association between PMVCs and outbreak risk at the province level over 34 African countries between 2005 and 77 2018.
 - 78 • Using this method, we compared pre- and post-PMVC period are compared within each province individually, thus controlling for all possible confounders that do not vary in time, 79 especially the fact that provinces indicated for PMVCs are generally those considered at 80 highest baseline risk of yellow fever (ie confounding by indication).
 - 81
 - 82 • At the province level, we estimated that implementation of PMVCs was associated with an 83 86% reduction (66% to 94%) in the risk of yellow fever outbreak.
 - 84 • Results from a complete cohort analysis provided less reliable results than the SCCS method, 85 likely because of confounding by indication that was not entirely controlled for by adjusting 86 on known drivers of yellow fever.
 - 87 • We further estimated that all PMVCs conducted between 2006 and 2018 in Africa may have 88 reduced the total number of yellow fever outbreaks by 34% (22% to 45%).

89 **What Do These Findings Mean?**

- 90
- 91 • These results provide new empirical evidence of the high preventive impact of PMVCs on yellow fever outbreaks.
 - 92 • These results may encourage rapid re-scheduling of yellow fever PMVCs that have been 93 postponed due to the COVID-19 pandemic.
 - 94 • The SCCS design may be advantageously applied at the population level to assess the impact 95 of public health interventions.

96

97

98 INTRODUCTION

99 Recent years have seen the resurgence of Yellow fever outbreaks in Africa and Latin America [1].
100 Regarding Africa specifically, five alerts have been issued for the first semester 2020 alone (Uganda,
101 South Sudan, Ethiopia, Togo, Gabon) [2]. As a response to the large-scale Angola 2015-2016
102 outbreak, the World Health Organization (WHO) launched the Eliminate Yellow fever Epidemics (EYE)
103 initiative in 2017 [3]. This strategy aims at preventing sporadic cases sparking urban outbreaks and
104 potentially triggering international spread. It relies on various vaccination activities, including
105 Preventive Mass Vaccination Campaigns (PMVCs) that target all or most age groups in a specific area.
106 Evaluating the health impact of such campaigns is key to inform further PMVCs within or beyond the
107 EYE strategy, to ensure population acceptance and adherence to vaccination campaigns, and to
108 sustain domestic and international efforts for vaccination activities.

109 Previous attempts were made in order to estimate the impact of vaccination activities, including
110 PMVCs [4–6]. These attempts mostly relied on mathematical models to estimate PMVCs impact in
111 terms of deaths or cases prevented on the long term. However, few studies aimed at quantifying the
112 effect of vaccination campaigns on the risk of outbreak. Regardless of the number of cases they may
113 generate, outbreaks can possibly lead to healthcare, economic and social destabilizations of entire
114 regions. As an example, the west-African 2013-2016 Ebola outbreak strained health systems and
115 generated fear of the disease. This caused excess deaths due to neglected need for malaria control
116 [7,8].

117 When assessed at the population level, the association of vaccination activities and risk of outbreak
118 can be approached within a classical epidemiological perspective. As individuals would be in a cohort
119 study, populations (for instance populations living in well-defined geographical areas) may be
120 followed over time while tracking both exposure (vaccination activities) and events (outbreaks). In
121 such observational studies, a risk of confounding arises when both exposure and event share a same
122 cause. This risk is high when measuring the association between PMVCs and yellow fever outbreaks
123 because PMVCs usually target areas that are assessed at particularly high risk by public health
124 officials, due to the disease circulation in the past or based on expert view or risk assessment [9].
125 Such a risk of confounding is usually overcome in the statistical analysis by conditioning, generally
126 adjusting, on the shared common cause; in this case the baseline risk of yellow fever in the area.
127 However, the environmental or demographic drivers of yellow fever are not fully understood [10,11],
128 leading to a situation in which residual confounders may bias the measure of association.

129 The self-controlled case series (SCCS) method is a case-only epidemiological study design for which
130 individuals are used as their own control [12]. As all known and unknown time-invariant confounding
131 are implicitly controlled for, the method is a relevant alternative to classical cohort or case-control
132 study designs when the risk of residual confounding is high. The SCCS method has successfully been
133 applied at the individual level, comparing exposure vs. non-exposure periods within individual cases
134 [13]. However, to our knowledge, this method has never been used for population-level case series
135 to evaluate the health effects of a public health intervention in specific regions, countries, or other
136 predefined geographical clusters that may be considered as group-level cases.

137 Here, we illustrate the use of the SCCS method at the population level by assessing the association
138 between the implementation of PMVCs and the occurrence of yellow fever outbreaks at the province
139 level in the African endemic region between 2005 and 2018.

140

141

142 **METHODS**

143 **Study hypotheses**

144 Considering the yellow fever vaccine's high level of efficacy [14], and given the fact that PMVCs
145 target all or most age groups in targeted areas, we expect to detect a substantial preventive effect of
146 PMVC on the risk of outbreak. We also expect to detect this association in a cohort design, providing
147 confounders in the association between exposure to PMVC and outbreak are adequately controlled
148 for (no model misspecification). A SCCS model would avoid the risk of residual confounding, at least
149 for time-independent variables, but would reduce statistical power as compared to a cohort-design
150 analysis [15].

151

152 **Data used**

153 This study relied on datasets that were previously collected and regularly updated for a broader
154 project aiming at estimating the burden of yellow fever and the impact of vaccine activities [4,6]. The
155 analytic plan was defined before the start of the analysis. This study did not require ethical approval.

156 In 2005, the African Regional Office of WHO established a yellow fever surveillance database across
157 21 countries in West and Central Africa based on reports of suspected yellow fever cases [4]. This is
158 likely to have influenced the standards of yellow fever surveillance in these countries. In order to
159 reduce the possible effect of time-changing surveillance quality, the beginning of the study period
160 was set at this date. We compiled location and dates of yellow fever outbreaks reported in Africa
161 between 2005 and 2018 from international epidemiological reports, namely the WHO Weekly
162 Epidemiological Reports (WER) and the Diseases Outbreak News (DON) [16,17]. As per WHO
163 recommendations, a single, confirmed yellow fever case is sufficient to justify outbreak investigation.
164 Based on the results of the investigation and on the absence of other suspected cases, an alert can
165 be classified as an isolated case, which was not considered for this study [18]. Locations were
166 resolved at the first sub-national administrative level, thereafter called province, and data were
167 recorded for each outbreak with the date of occurrence. Outbreak reports that could not be located
168 at the province level were excluded.

169 We compiled data regarding PMVCs conducted as part of the Yellow Fever initiative since 2006 [19],
170 and additional campaigns further conducted under the EYE strategy [1]. Starting dates and locations
171 of PMVCs were collected, and the resulting list of vaccination campaigns was compared with data
172 from the WHO International Coordinating Group (ICG) on Vaccine Provision, while resolving any
173 discrepancy. This virtually ensured completeness of information regarding mass vaccination
174 activities. Note that information on the vaccine strain used for each PMVCs are not widely available,
175 however, both vaccine strains recommended by the WHO (17D and 17DD) do not differ in terms of
176 immunogenicity [14,20]. PMVCs considered here implied full-dose vaccine only as fractional-dose

177 vaccination has been approved by WHO only as part of an emergency response to an outbreak if
178 there is a shortage of full-dose YF vaccine [21].

179 Estimates of population-level vaccine-induced protection against yellow fever were obtained from
180 Hamlet et al [22]. These estimates were obtained by compiling regularly updated vaccination data
181 from different sources (routine infant vaccination, reactive campaigns, PMVCs) and inputting these
182 into a demographic model.

183

184 ***Main SCCS analysis***

185 For our main analysis, we used the SCCS method to estimate the incidence rate ratio (IRR) of yellow
186 fever outbreak after vs. before the implementation of a PMVC. We used the province as unit of
187 analysis, so that the main outcome represents the risk for a province to be affected by an outbreak.
188 As the dependency between potential outbreak recurrences in the same province could not be
189 excluded, we limited the analyses to the first outbreak occurrence per province for the main analysis
190 [23]. We used a conditional Poisson model with logit link to model the occurrence of outbreaks [15].

191 Provinces included in the SCCS analysis were those both affected by an outbreak and targeted for a
192 PMVC over a study period from Jan 1st 2005 to Dec 31st 2018. We defined the unexposed period as
193 the pre-PMVC period. Previous research found that a single dose of yellow fever vaccine provides a
194 long-lasting immunity with high efficacy [14,20]. Therefore, and given the relatively short observation
195 period of the study (14 years), we assumed the exposure period started at the date of the first PMVC
196 and lasted until the end of the observation period. This assumption was made regardless of
197 estimated achieved coverage or intra-province geographic extent of the campaigns. In other terms,
198 we assumed the campaigns achieved uniform high coverage in all age groups across provinces and
199 that this high coverage was maintained up to the end of the study period. This assumption of
200 persisting high coverage is further justified by the inclusion of yellow fever vaccine in the Enhanced
201 Program of Immunization of most of the countries in the study region [24]. Routine infant
202 vaccination may not rapidly increase population-level immunity by itself, but does contribute to
203 maintain high levels once achieved by the means of PMVCs.

204

205 ***Alternative SCCS models and sensitivity analyses***

206 In order to allow for possible variation in coverages achieved across PMVCs, we considered the
207 estimated population-level vaccine coverage as an alternative time-varying, quantitative exposure
208 (considered as categories with 20% bandwidth: 0-19% / 20-39% / 40-59% / 60-79% / 80-100%).

209 We also used alternative SCCS models to assess the influence of several assumptions on our results
210 (Table 1) [12]. We conducted a SCCS analysis considering all outbreaks, instead of the first one only,
211 in order to evaluate the influence of the assumption of non-independent recurrence. Additionally, as
212 it is possible that the occurrence of an outbreak could affect subsequent exposure, we conducted a
213 SCCS analysis including a 3-year pre-exposure period.

214 As the precise date of outbreaks and PMVCs start were not always available, we assumed where
215 missing, that outbreaks started in the middle of the year and that exposure to PMVCs started at the
216 end of the year. The influence of these assumptions was explored in sensitivity analysis.

217 Furthermore, to assess how the choice of the study period influenced our results, we also conducted
218 a sensitivity analysis considering alternative start and end dates: i) Jan 1st 2007 to Dec 31st 2018, and
219 ii) Jan 1st 2005 to Dec 31st 2014.

220 Lastly, to assess whether spatial autocorrelation could affect our results, we conducted multiple re-
221 sampling. In each re-sampling from the SCCS study sample, we only sampled one random province
222 per country and re-estimated the IRR of the association between exposure and the event. This
223 implicitly accounts for spatial autocorrelation within, but not across countries.

224

225 ***Analysis using the cohort design***

226 We compared the results obtained using the SCCS method with those obtained using a classical
227 cohort design. The study sample was constituted of all provinces belonging to the 34 African
228 countries at high or moderate risk for yellow fever [3]. We used univariate and multivariate Poisson
229 regression models with robust variance, considering exposure alternatively as a binary (pre- versus
230 post-PMVC) or continuous (vaccination coverage) time-dependent variable.

231 In a cohort design, the choice of covariates to include is critical to prevent bias due to residual
232 confounding. However, there is currently no clear consensus about the demographical and
233 environmental drivers of yellow fever. We thus considered two (partially overlapping) sets of
234 covariates (Supplementary Text S1). Both sets of variables were documented to reproduce well the
235 presence and absence of yellow fever records at the province level. The first set of covariates was
236 previously used in a statistical model whereas the second was used in a mechanistic model. [4,10]
237 Statistical models aim to describe the patterns of association between species (including infectious
238 agents species) and environmental variables while mechanistic models aim at explicitly representing
239 biological processes in their occurrence [25]. The association between each covariate and the
240 exposure status was explored using modified Poisson regression.

241

242 **Number of outbreaks averted and prevented fraction**

243 For each province i , we estimated the expected number of outbreaks averted by PMVC, A_i , using the
244 formula:

$$A_i = \lambda_i(T - d_i)(1 - IRR) \quad (1)$$

245 Where T is the total time of observation, d_i is the time at which PMVC was implemented (if no PMVC
246 in province i , thus $d_i = T$), λ_i is the rate of outbreak occurrence in a Poisson process in the absence
247 of PMVC, and IRR is the incidence rate ratio after vs. before PMVC implementation. With N_i^{E-} being
248 the number of outbreaks observed in the province i during the pre-PMVC, an estimator of λ_i is
249 $\hat{\lambda}_i = N_i^{E-}/d_i$, which leads to:

$$\hat{A} = \sum_i \frac{N_i^{E-}(T - d_i)}{d_i} (1 - \widehat{IRR}) \quad (2)$$

250 We obtained 95% confidence intervals for A using bootstrap (10,000 resampling). For each
251 resampling, a value of IRR was randomly sampled based on the parameters estimated in the SCCS
252 analysis.

253 Finally, based on \hat{A} and N , the total number of outbreaks observed, we obtained the outbreaks
254 prevented fraction, PF , with:

$$PF = 1 - \frac{N}{N + \hat{A}} \quad (3)$$

255
256

Table 1: Analysis plan for the measure of the association between yellow fever vaccination activities and outbreak risk. SCCS: Self-controlled case series.

257

Model	Outcome		Exposure			Covariates		
	1 st outbreak only	Repeated outbreaks included	Binary exposure: pre- vs. post-PMVC	Inclusion of a 3-year pre-exposure window period	Quantitative estimates of population-level vaccination coverage	None (self-controlled)	Covariates used in a previous statistical model	Covariates used in a previous mechanistic model
SCCS Model 1 (main analysis)	X		X			X		
SCCS Model 2		X	X			X		
SCCS Model 3	X			X		X		
SCCS Model 4	X				X	X		
Cohort model 1	X		X				X	
Cohort model 2	X				X		X	
Cohort model 3	X		X					X
Cohort model 4	X				X			X

267

PMVC: preventive mass vaccination campaign.

268 RESULTS


269 *Outbreak occurrence and PMVCs*

270 A total of 96 outbreaks out of 97 records (99.0%) were geographically resolved. Among the 479
271 provinces within the African endemic or at-risk region for yellow fever, 81 (16.9%) from 18 countries
272 (of 34 countries) experienced at least one yellow fever outbreak between 2005 and 2018 (Figure 1A),
273 including 12 provinces experiencing more than one outbreak. The Poisson probability distribution
274 applied satisfactorily to the observed outbreaks distribution (Supplementary Table S1). Overall, 124
275 (25.9%) provinces were targeted for at least one PMVC (Figure 1B). The SCCS study sample was
276 constituted from 33 (6.9%) provinces having experienced both outbreak and PMVC implementation
277 over the study period. Temporal trends in the estimated population-level vaccination coverage for
278 this sample are displayed in supplementary material (Supplementary Figure S1). The median of the
279 difference between the post- and the pre-PMVC estimate of vaccination coverage was 24.2% (inter-
280 quartile range: 9.4 – 42.7%) (Supplementary Figure S2).

281

282

283



284

285 **Figure 1:** Occurrence of yellow fever outbreaks (A) and preventive mass vaccination campaigns (B) at
286 the province level over the 2005-2018 period. Maps were produced from GADM version 2.0.


287

288

289 *SCCS analysis*

290 Among the SCCS study sample, the first outbreak occurred during the unexposed period in 26
291 (78.8%) provinces versus 7 (21.2%) occurring in the exposure period (Figure 2). Under baseline
292 assumptions, this corresponded to a significantly reduced incidence rate ratio of 0.14 (95%

293 Confidence interval, CI: 0.06 – 0.34) for the exposed versus unexposed periods. A similar protective
294 association was observed when considering all outbreaks instead of the first one only (IRR = 0.19,
295 95% CI 0.09 – 0.39) or when including a 3-year pre-exposure period (IRR = 0.14, 95% CI 0.05 – 0.40).
296



297

298 **Figure 2:** Swimmer plot of the chronology of exposure to preventive mass vaccination campaigns
299 (PMVCs) and yellow fever outbreaks among the 33 exposed cases African provinces (2005-2018). A:
300 Time distribution of yellow fever outbreaks. B : Swimmer plot. The 3-digit code on the y-axis refers to
301 countries ISO codes (see Supplementary Table S2 for complete province and country names).

302

303 Considering estimates of population-level vaccine coverage as a categorical variable based on 20%
304 allowed observing a reduced risk of outbreak for higher levels of coverage (Table 2). Considering
305 vaccine coverage as a continuous linear exposure ensured a better fit of the model (likelihood ratio
306 test: $p=0.44$). Doing so, we estimated that a 10%-increase in vaccine coverage was associated with a
307 risk of outbreak decreased by 41% (IRR 0.59; 95% CI 0.46 – 0.76).

308

309 *Sensitivity analysis*

310 The negative association between exposure to PMVCs and outbreak remained significant across a
311 range of assumptions regarding the imputation of the date (within the same year) of PMVCs
312 implementation and outbreak starting date (when missing), and across various observation periods
313 (Supplementary Table S3 and S4).

314 When re-sampling 100 times the SCCS study sample while allowing only one sampled province per
315 country, and after excluding re-sampling yielding to random zero in the corresponding contingency
316 table (N=16 with no outbreak occurring during exposed periods, thus leading to infinite confidence

317 interval surrounding the association measure), we obtained an averaged IRR of 0.09 (95% CI 0.01-
318 0.62).

319

320 **Table 2:** Association between exposure to preventive mass vaccination campaigns (PMVCs) and
321 yellow fever outbreak in African provinces, 2005-2018.

Model	Exposure category	Number of events	IRR*	95% confidence interval
SCCS Model 1 (main analysis)	Unexposed (Ref.)	26	1.00	-
	Exposed	7	0.14	0.06-0.34
SCCS Model 2 (all outbreaks)	Unexposed (Ref.)	32	1.00	-
	Exposed	11	0.19	0.09-0.39
SCCS Model 3	Unexposed (Ref.)	11	1.00	Ref.
	Pre-exposed (3 years)	15	0.99	0.42-2.30
	Exposed	7	0.14	0.05-0.40
SCCS Model 4	$V_c < 0.2$	6	0.61	0.11-3.27
	$0.2 \leq V_c < 0.4$	10	2.40	0.61-9.41
	$0.4 \leq V_c < 0.6$ (Ref.)	8	1.00	-
	$0.6 \leq V_c < 0.8$	5	0.29	0.06-1.41
	$0.8 \leq V_c \leq 1$	4	0.05	0.01-0.28
Cohort model 1 (statistical model)	Unexposed (Ref.)	74	1.00	-
	Exposed	7	0.37	0.15-0.92
Cohort model 2 (statistical model)	$V_c < 0.2$	19	0.18	0.07-0.50
	$0.2 \leq V_c < 0.4$	40	0.86	0.43-1.73
	$0.4 \leq V_c < 0.6$ (Ref.)	13	1.00	-
	$0.6 \leq V_c < 0.8$	5	0.49	0.17-1.40
	$0.8 \leq V_c \leq 1$	4	0.11	0.03-0.36
Cohort model 3 (mechanistic model)	Unexposed (Ref.)	74	1.00	-
	Exposed	7	0.65	0.26-1.65
Cohort model 4 (mechanistic model)	$V_c < 0.2$	19	0.07	0.03-0.18
	$0.2 \leq V_c < 0.4$	40	0.77	0.40-1.48
	$0.4 \leq V_c < 0.6$ (Ref.)	13	1.00	-
	$0.6 \leq V_c < 0.8$	5	0.47	0.16-1.40
	$0.8 \leq V_c \leq 1$	4	0.13	0.04-0.41

322 IRR: Incidence rate ratio. V_c : population-level vaccination coverage.* For cohort models, IRR are
323 adjusted on several demographic and environmental covariates, depending of the model (statistical
324 or mechanistic), see Supplementary Tables S5 to S7.

325

326 *Cohort-style analysis*

327 In a cohort design, over the 81 outbreaks (first outbreaks only) that occurred over the study period,
328 74 occurred during unexposed periods versus 7 occurring in exposed periods. Most of the
329 environmental covariates we explored were associated with exposure to PMVCs (Supplementary
330 Table S5). Exposure to PMVCs was associated to a significant reduced risk of outbreak (IRR = 0.37,
331 95% CI 0.15-0.92) when adjusting on the covariates obtained from a statistical model. When
332 adjusting on covariates obtained from a mechanistic model, exposure to PMVC was not significantly
333 associated with the risk of outbreak (IRR=0.65, 95% CI 0.26-1.65) (detailed results in Supplementary
334 Tables S6 and S7). For both sets of covariates, we observed an inversed U-shaped association
335 between the estimates of vaccination coverage and the risk of outbreak, with the risk decreasing for
336 lowest and highest values of vaccination coverage (Table 2).

337

338 *Number of outbreaks averted and prevented fraction*

339 Based on the value of IRR estimated in the main analysis (IRR = 0.14, 95% CI 0.06 – 0.34), we
340 estimated that PMVCs implemented over the study period averted in median 50 (28 to 80)
341 outbreaks. When considering a total of 96 outbreaks occurring over the considered time period, this
342 corresponds to a prevented fraction of 34% (22% to 45%).

343

344

345 **DISCUSSION**

346 In this paper, using the SCCS method, we quantified the preventive effect of PMVCs on the risk of
347 outbreak at the province level, documenting a 86% (95% CI 66 to 94%) reduction of the risk of
348 outbreak occurrence for provinces that were targeted by a PMVC. This result was robust over a range
349 of assumptions. When using an estimate of population-level coverage as exposure, we also observed
350 a dose-response preventive effect on the risk of outbreak. Considering the scale of PMVCs
351 implementation during the study period, this corresponded to an estimated 22% to 45% of outbreaks
352 averted by PMVCs in Africa between 2005 and 2018. Based on a cohort design analysis, the
353 association between PMVC and outbreak was sensitive to the choice of adjustment variables.
354 Moreover, we observed a challenging U-shape association between vaccination coverage and the risk
355 of outbreak in the cohort analysis. Overall, these results suggest a risk of residual confounding that
356 the SCCS method, but not cohort design, could overcome, at least for time-independent confounder.
357 To our knowledge, this is the first time a SCCS analysis was conducted at the population level.

358 Considering evidence of yellow fever vaccine efficacy at the individual level, a preventive effect of
359 PMVC on outbreak risk was indeed expected. This is why we think that the cohort analysis results
360 may be biased by residual confounding ; whereas we consider the results obtained from the SCCS
361 method to be more trustworthy. Indeed, the indication of provinces for PMVCs partly relies on a risk
362 assessment [3]. For the results of the cohort-design analysis to be valid, one needs to account for all
363 possible confounders in the association between PMVCs and outbreak. This is particularly challenging
364 as the environmental and demographic drivers of yellow fever are not fully understood yet [9].

365 Another result suggesting residual confounding in the cohort-design analysis is the U-shaped
366 relationship between vaccination coverage and outbreak risk. The yellow fever vaccine has not been
367 introduced in large regions of Eastern Africa yet, as the risk of yellow fever is usually considered as
368 low, though existing (eg. Kenya). This setting can actually yield to a spurious negative association
369 between low level of vaccination coverage and outbreak risk when confounders are not controlled
370 for. In the SCCS analysis, we did observe a linear relationship in the expected association between
371 vaccination coverage and outbreak risk, which stands as another evidence for reduced residual
372 confounding as compared to the cohort analysis. Analysing cases only, instead of the corresponding
373 complete cohort, translates into a loss of efficiency, but previous work showed that this loss is small,
374 especially when the fraction of the sample experiencing the exposure is high [26]. Moreover, this loss
375 of efficiency has to be weighed against a better control of time-invariant confounders. Previous
376 examples illustrated that the SCCS design is likely to produce more trustful results than the
377 corresponding cohort analysis, especially when a strong indication bias is likely [27,28].

378 Although the SCCS method has been originally developed to be conducted at the individual level, we
379 ensured that our analysis complied with all its requirements [12,15]. Exposure and outcomes were
380 ascertained independently. The list of PMVCs was compiled based on information provided by
381 international funders. Outbreak occurrence were compiled from WHO sources, which themselves
382 compile outbreak notification from countries as per the 2005 International Health Regulation. The
383 observation period was chosen in order to maximize the chance that cases experienced the exposure
384 period. Indeed, our observation period started few times before the launch of the first Yellow Fever
385 initiative, which boosted the use of PMVCs that have been very rare since the 1960s [4,19]. The
386 choice of the long and unlimited exposure period was based on evidence regarding the long-lasting
387 protection conferred by the yellow fever vaccine, and the SCCS method has been previously used
388 successfully while considering long and unlimited risk periods [29]. The application of the SCCS design
389 at the population level certainly deserves further methodological assessments to ensure its
390 robustness to specific issues when transposing it at the population level, especially those related to
391 over-dispersed or auto-correlated events. We hope that the present work will stimulate further
392 studies characterizing the advantage and drawbacks of SCCS as compared to more classically used
393 population-level designs, for instance interrupted time-series.

394 Under the assumption of causality, the incidence risk ratio we estimate represents the average effect
395 for a province of being targeted by a PMVC, which corresponds to the average treatment effect in
396 the counterfactual framework. This average effect is likely to mask large heterogeneity in the local
397 effect of PMVC. Indeed, PMVCs occur in population with various baseline levels of immunity, and
398 they may achieve various levels of post-intervention coverage. The dose-response relationship we
399 observed in the association between vaccination coverage and outbreak risk brought additional
400 evidence for a causal link between PMVC and reduced outbreak risk. When looking at higher values
401 of vaccination coverage, it is notable that several outbreaks (n=4) occurred at estimated levels of
402 vaccination coverage >80%, an empirical threshold that has been often suggested as protecting from
403 outbreaks [30]. While keeping in mind all the limitations such province-based estimates of
404 vaccination coverage may have (outbreaks could occur in small pockets with low vaccination
405 coverage even in provinces with high coverage), this can be viewed an argument to ensure high
406 vaccination coverages homogeneously in at-risk areas, and to sustain them after PMVCs by ensuring
407 routine infant vaccination.

408 Relying on our estimate of the preventive effect of PMVC, the timing of implementation of these
409 PMVCs and the number outbreaks observed during the study period, we further estimated that
410 PMVCs have averted from 28 to 80 outbreaks in Africa between 2005 and 2018, corresponding to a
411 prevented fraction lying between 22% to 45%. Garske et al. previously estimated that vaccination
412 campaigns conducted up to 2013 averted between 22 to 31% of yellow fever cases and deaths in
413 Africa, while Shearer et al estimated that all vaccination activities (including routine infant
414 vaccination) conducted up to 2016 have averted 33 to 39% of cases [4,5]. Our estimates were in a
415 comparable range, although direct comparison with these model-based estimates is not
416 straightforward. Indeed the latter are expressed as proportions of all yellow fever cases, including
417 sylvatic cases that are not linked to outbreaks. Preventing outbreaks of epidemic prone diseases is
418 critical for ensuring global health security yet there are few empirical studies that quantify the impact
419 of public health interventions like immunization have on the risk of outbreaks.

420 A main limitation of our study is that it does not account for possible time-varying confounders.
421 Environmental changes affecting vector-borne diseases have been documented across tropical Africa
422 over the study period, probably the main being changing land-use such as deforestation [31,32].
423 More frequent intrusions of humans into forest and jungles, together with increasing human mobility
424 between endemic and non-endemic areas, have also been suggested to have affected the yellow
425 fever risk in the recent period [33]. Similarly, recent international emphasis about yellow fever may
426 have led to better surveillance of the disease in the recent years. However, these various factors are
427 likely to have increased the risk of outbreaks and the probability of outbreak detection in the recent
428 period, which overlaps with the post-PMVCs period in our study sample. This may have led to an
429 underestimate of the association between PMVC and yellow fever outbreaks. Lastly, historical
430 vaccination activities that occurred up to the 1970s may potentially act as a time-varying confounder.
431 Indeed, the contribution of older people (those potentially exposed to these historical campaigns) to
432 the population-level immunity may decrease over time by population renewal. However, the
433 corresponding bias is likely limited considering the population structure skewed towards younger
434 individuals in the region considered here. Moreover, such a bias is likely to have led to an under-
435 evaluation of the association between PMVC and yellow fever outbreaks. Indeed, decreasing
436 population-level immunity would have increased the risk of outbreak during the more-recent period,
437 which corresponds to the post-PMVCs period. Previous quantification of the outstanding health
438 impact of vaccination activities have mainly focused on cases or deaths prevented while relying on
439 mathematical models, which structures and assumptions may be difficult to understand by a non-
440 expert audience, whether it be decision-makers or targeted populations [34,35]. Here we further
441 document this impact using an empirical, maybe more intuitive approach thus allowing for a
442 triangulation of methods to further document the beneficial impact of yellow fever vaccine
443 campaigns. This method relies on data that are quite easily accessible. Thus, our method could be
444 applied to other diseases for which PMVCs are implemented, such as polio, meningitis or cholera.
445 Due to the COVID-19 pandemic, WHO recommended to temporarily suspend preventive campaigns
446 while assessments of risk, and effective measures for reducing COVID-19 circulation were
447 established. In consequence, regarding yellow fever specifically, four countries postponed
448 vaccination campaigns [36]. Our results provide additional evidence to encourage a rapid
449 rescheduling of these vaccine campaigns in order to prevent further outbreaks of preventable
450 disease.

451

452 **Acknowledgment**

453 We are thankful to Paddy Farrington for helpful discussions.

454

455

456 **REFERENCES**

- 457 1. World Health Organization. Yellow fever in Africa and the Americas, 2018. *Wkly Epidemiol Rec.*
458 2019;94: 365–380.
- 459 2. WHO Disease Outbreak News (DONs). [cited 3 Jul 2020]. Available:
460 https://www.who.int/csr/don/archive/disease/yellow_fever/en/
- 461 3. World Health Organization. Eliminate Yellow fever Epidemics (EYE): a global strategy, 2017–
462 2026. *Wkly Epidemiol Rec.* 2017;92: 193–204.
- 463 4. Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE, et al. Yellow Fever in
464 Africa: estimating the burden of disease and impact of mass vaccination from outbreak and
465 serological data. *PLoS Med.* 2014;11: e1001638. doi:10.1371/journal.pmed.1001638
- 466 5. Shearer FM, Longbottom J, Browne AJ, Pigott DM, Brady OJ, Kraemer MUG, et al. Existing and
467 potential infection risk zones of yellow fever worldwide: a modelling analysis. *The Lancet Global*
468 *Health.* 2018;0. doi:10.1016/S2214-109X(18)30024-X
- 469 6. Jean K, Hamlet A, Benzler J, Cibrelus L, Gaythorpe KAM, Sall A, et al. Eliminating yellow fever
470 epidemics in Africa: Vaccine demand forecast and impact modelling. *PLOS Neglected Tropical*
471 *Diseases.* 2020;14: e0008304. doi:10.1371/journal.pntd.0008304
- 472 7. WHO Global Malaria Programme. Guidance on temporary malaria control measures in Ebola-
473 affected countries. 2014. Available:
474 [https://apps.who.int/iris/bitstream/handle/10665/141493/WHO_HTM_GMP_2014.10_eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/141493/WHO_HTM_GMP_2014.10_eng.pdf?sessionid=8F680505C5FC344148A5579ECB07BC40?sequence=1)
475 [;jsessionid=8F680505C5FC344148A5579ECB07BC40?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/141493/WHO_HTM_GMP_2014.10_eng.pdf?sessionid=8F680505C5FC344148A5579ECB07BC40?sequence=1)
- 476 8. Walker PGT, White MT, Griffin JT, Reynolds A, Ferguson NM, Ghani AC. Malaria morbidity and
477 mortality in Ebola-affected countries caused by decreased health-care capacity, and the
478 potential effect of mitigation strategies: a modelling analysis. *Lancet Infect Dis.* 2015;15: 825–
479 832. doi:10.1016/S1473-3099(15)70124-6
- 480 9. Jentes ES, Pomeroy G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, et al. The revised global
481 yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal
482 WHO Working Group on Geographic Risk for Yellow Fever. *The Lancet Infectious Diseases.*
483 2011;11: 622–632. doi:10.1016/S1473-3099(11)70147-5
- 484 10. Hamlet A, Jean K, Perea W, Yactayo S, Biey J, Kerkhove MV, et al. The seasonal influence of
485 climate and environment on yellow fever transmission across Africa. *PLOS Neglected Tropical*
486 *Diseases.* 2018;12: e0006284. doi:10.1371/journal.pntd.0006284
- 487 11. Monath TP, Vasconcelos PFC. Yellow fever. *Journal of Clinical Virology.* 2015;64: 160–173.
488 doi:10.1016/j.jcv.2014.08.030
- 489 12. Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to
490 standard epidemiological study designs. *BMJ.* 2016;354: i4515. doi:10.1136/bmj.i4515
- 491 13. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation.
492 *Biometrics.* 1995;51: 228–235.

- 493 14. Jean K, Donnelly CA, Ferguson NM, Garske T. A Meta-Analysis of Serological Response
494 Associated with Yellow Fever Vaccination. *The American Journal of Tropical Medicine and*
495 *Hygiene*. 2016;95: 1435–1439. doi:10.4269/ajtmh.16-0401
- 496 15. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled
497 case series method. *Stat Med*. 2006;25: 1768–1797. doi:10.1002/sim.2302
- 498 16. World Health Organization. Weekly Epidemiological Record (WER). World Health Organization;
499 Available: <https://www.who.int/wer/en/>
- 500 17. World Health Organization. Disease Outbreak News (DON). World Health Organization;
501 Available: <https://www.who.int/csr/don/en/>
- 502 18. World Health Organization. Yellow fever surveillance and outbreak response: revision of case
503 definitions, October 2010. *Wkly Epidemiol Rec*. 2010;85: 465–472.
- 504 19. World Health Organization. The Yellow fever initiative: an introduction. 2016. Available:
505 <https://www.who.int/csr/disease/yellowfev/introduction/en/>
- 506 20. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever
507 vaccination: systematic review on the need for a booster every 10 years. *Am J Trop Med Hyg*.
508 2013;89: 434–444. doi:10.4269/ajtmh.13-0264
- 509 21. Vannice K, Wilder-Smith A, Hombach J. Fractional-Dose Yellow Fever Vaccination — Advancing
510 the Evidence Base. *New England Journal of Medicine*. 2018;379: 603–605.
511 doi:10.1056/NEJMp1803433
- 512 22. Hamlet A, Jean K, Yactayo S, Benzler J, Cibrelus L, Ferguson N, et al. POLICI: A web application
513 for visualising and extracting yellow fever vaccination coverage in Africa. *Vaccine*. 2019;37:
514 1384–1388. doi:10.1016/j.vaccine.2019.01.074
- 515 23. Simpson SE. A positive event dependence model for self-controlled case series with
516 applications in postmarketing surveillance. *Biometrics*. 2013;69: 128–136. doi:10.1111/j.1541-
517 0420.2012.01795.x
- 518 24. World Health Organization. Yellow fever in Africa and the Americas, 2015. *Wkly Epidemiol Rec*.
519 2016;91: 381–388.
- 520 25. Dormann CF, Schymanski SJ, Cabral J, Chuine I, Graham C, Hartig F, et al. Correlation and
521 process in species distribution models: bridging a dichotomy. *Journal of Biogeography*. 2012;39:
522 2119–2131. doi:10.1111/j.1365-2699.2011.02659.x
- 523 26. Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies.
524 *Stat Methods Med Res*. 2009;18: 7–26. doi:10.1177/0962280208092342
- 525 27. Kramarz P, DeStefano F, Gargiullo PM, Davis RL, Chen RT, Mullooly JP, et al. Does influenza
526 vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. *Vaccine*
527 *Safety Datalink Team*. *Arch Fam Med*. 2000;9: 617–623. doi:10.1001/archfami.9.7.617
- 528 28. Douglas IJ, Evans SJW, Hingorani AD, Grosso AM, Timmis A, Hemingway H, et al. Clopidogrel
529 and interaction with proton pump inhibitors: comparison between cohort and within person
530 study designs. *BMJ*. 2012;345. doi:10.1136/bmj.e4388

- 531 29. Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J, et al. Autism and
532 measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association.
533 *Lancet*. 1999;353: 2026–2029. doi:10.1016/s0140-6736(99)01239-8
- 534 30. World Health Organization. Yellow fever key facts. 1 May 2018. Available:
535 <http://www.who.int/en/news-room/fact-sheets/detail/yellow-fever>
- 536 31. Faust CL, McCallum HI, Bloomfield LSP, Gottdenker NL, Gillespie TR, Torney CJ, et al. Pathogen
537 spillover during land conversion. *Ecology Letters*. 2018;21: 471–483. doi:10.1111/ele.12904
- 538 32. Esser HJ, Mögling R, Cleton NB, van der Jeugd H, Sprong H, Stroo A, et al. Risk factors associated
539 with sustained circulation of six zoonotic arboviruses: a systematic review for selection of
540 surveillance sites in non-endemic areas. *Parasites & Vectors*. 2019;12: 265.
541 doi:10.1186/s13071-019-3515-7
- 542 33. World Health Organization, UNICEF, GAVI. A global strategy to Eliminate Yellow fever Epidemics
543 (EYE): 2017–2026. 2017. Available:
544 <https://apps.who.int/iris/bitstream/handle/10665/272408/9789241513661-eng.pdf>
- 545 34. Chang AY, Riumallo-Herl C, Perales NA, Clark S, Clark A, Constenla D, et al. The Equity Impact
546 Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries.
547 *Health Aff (Millwood)*. 2018;37: 316–324. doi:10.1377/hlthaff.2017.0861
- 548 35. Li X, Mukandavire C, Cucunubá ZM, Abbas K, Clapham HE, Jit M, et al. Estimating the health
549 impact of vaccination against 10 pathogens in 98 low and middle income countries from 2000
550 to 2030. *medRxiv [preprint]*. 2019; 19004358. doi:10.1101/19004358
- 551 36. World Health Organization. At least 80 million children under one at risk of diseases such as
552 diphtheria, measles and polio as COVID-19 disrupts routine vaccination efforts, warn Gavi,
553 WHO and UNICEF. 22 May 2020 [cited 9 Jun 2020]. Available: [https://www.who.int/news-
554 room/detail/22-05-2020-at-least-80-million-children-under-one-at-risk-of-diseases-such-as-
555 diphtheria-measles-and-polio-as-covid-19-disrupts-routine-vaccination-efforts-warn-gavi-who-
556 and-unicef](https://www.who.int/news-room/detail/22-05-2020-at-least-80-million-children-under-one-at-risk-of-diseases-such-as-diphtheria-measles-and-polio-as-covid-19-disrupts-routine-vaccination-efforts-warn-gavi-who-and-unicef)
- 557